Profit from Our Great Societal Transformation
Markets go up and down. It happens. There will be bull markets and bear markets. Different administrations will come into power. Change is one of the few constants in life and investing.
But certain powerful and ascendant trends will regardless...
Read More
Should I Stay or Should I Go?
by Tom Hutchinson
My name is Tom Hutchinson. Starting next month I will be taking over as Chief Analyst of Cabot Dividend Investor. I’m excited to share the fruits of my life’s work and passion by giving you and...
Read More
Approaching Neutral
The major stock market indexes tacked on more losses last week, even though markets were only open for three-and-a-half days and trading was relatively light. The Nasdaq closed the week 4.3% lower, the Dow was down 4.4%, and the S&P 500 lost But...
Read More
Buying biotech stocks seems like a contrarian play at the moment. But it made one day trader a lot of money. Here's what it says about the current market.
Read More
This global pharma stock declined after merger buzz collapsed, but is gaining notice since the FDA just approved its new lung cancer drug. The shares have a current dividend yield of 2.88%, paid twice a year.
AstraZeneca (AZN)
From 2 for 1 Stock Split Newsletter
AstraZeneca was...
Read More
By Paul Goodwin
Editor, Cabot China & Emerging Markets Report
Here are the 24 Top Stocks of 2011. I screened the entire market to eliminate penny stocks and thinly traded issues that didn’t average 50,000 shares traded per day.
The overarching lesson of this list that...
Read More
Six out of the ten best-performing stocks of 2011 were in the medicine business.
Read More
